Minerva Neurosciences (NASDAQ:NERV) & UCB (OTCMKTS:UCBJY) Head to Head Analysis

UCB (OTCMKTS:UCBJY) and Minerva Neurosciences (NASDAQ:NERV) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Valuation and Earnings

This table compares UCB and Minerva Neurosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UCB	$6.66 billion	N/A	$1.15 billion	N/A	N/A
Minerva Neurosciences	N/A	N/A	$1.44 million	($1.85)	-2.19

UCB has higher revenue and earnings than Minerva Neurosciences.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for UCB and Minerva Neurosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
UCB	0	1	0	1	3.00
Minerva Neurosciences	1	1	0	0	1.50

Minerva Neurosciences has a consensus price target of $4.00, indicating a potential downside of 1.48%. Given Minerva Neurosciences’ higher probable upside, analysts plainly believe Minerva Neurosciences is more favorable than UCB.

Risk & Volatility

UCB has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500.

Institutional & Insider Ownership

34.6% of Minerva Neurosciences shares are held by institutional investors. 10.4% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares UCB and Minerva Neurosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
UCB	N/A	N/A	N/A
Minerva Neurosciences	N/A	-41.35%	-43.68%

Summary

UCB beats Minerva Neurosciences on 7 of the 10 factors compared between the two stocks.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

About Minerva Neurosciences

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.